Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

Local AIDS experts are at odds with the United Nations Programme on HIV/AIDS (UNAIDS) over its claims that AIDS could be ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...

The 2024 breakthrough of the year, according to the journal Science, was with the drug lenacapavir, an antiretroviral medicine that performed very well in scientific trials. Dr. Robert Hopkins Jr ...

Dr. Reddy's Laboratories Limited RDY reported third-quarter fiscal 2025 earnings of 20 cents per American Depositary Share ...

This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.

Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency ...

Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo ...

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...